GNL Director Featured at IMM Seminar Series at University Health Science Center in Houston

Dr. Gary Kobinger, GNL Director and the John Sealy Distinguished University Chair in Tropical and Emerging Virology at UTMB, will be the featured speaker in the UTHealth-Houston McGovern School of Medicine's Institute for Molecular Medicine (IMM) Seminar Series, to be held on Jan. 16 in the Beth Robertson Auditorium on the University of Texas Health Science Center at Houston campus.

Dr. Kobinger will share his insights on “The current world of biosafety level 4 R&D: surveillance, vaccines and therapeutics."

The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM) at The University of Texas Health Science Center at Houston was established in 1995.The IMM is focused on studying and preventing diseases at the genetic, cellular and molecular levels using DNA and protein technologies and animal models. The IMM is part of the Texas Therapeutics Institute, a multi-institutional collaboration encouraging drug discovery.

Dr. Kobinger is the Interim Director for the Sealy Institute for Drug Discovery at UTMB. This new institute at UTMB capitalizes on the institution's world-class research in infectious disease, neuroscience, and other disciplines for therapeutics development. The goal for the SIDD is that through academic and industrial partnerships, the Institute can integrate the best interdisciplinary teams to discover small molecules and biologics for the treatment of diseases. 

Collaborations between institutions, particularly others within the UT System, offer exciting opportunities for accelerated drug development and scientific advancements. Dr. Kobinger was hosted in Houston by Dr. Zhiqiang An, Professor and the Robert A. Welch Distinguished University Chair. Dr. Ang also directs the Texas Therapeutics Institute in Chemistry and serves as the university's Vice President of Drug Discovery.